IMUX Live signals | Maximize Profits with Getagraph.com

BUY 101522 min ago

@ $1.320

Issued: 14 Feb 2024 @ 15:57

Return: -6.06%

Previous signal: Feb 9 - 09:39

Previous signal: Sell

Return: 4.35 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases...

Stats
Today's Volume	129 677
Average Volume	595 170
Market Cap	111.51M
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.270 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.00600 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Howson Tamar D	Buy	64 959	Stock Option
2024-03-04	Howson Tamar D	Sell	10 000	Stock Option
2024-03-04	Howson Tamar D	Sell	10 000	Stock Option
2024-03-04	Howson Tamar D	Sell	9 986	Stock Option
2024-03-04	Howson Tamar D	Sell	15 000	Stock Option

INSIDER POWER
44.59
Last 97 transactions
Buy: 5 390 136 \| Sell: 1 509 904

Volume Correlation

Long: -0.09 (neutral)

Short: 0.37 (neutral)

Signal:(55.97) Neutral

Immunic Inc Correlation

10 Most Positive Correlations
TOP	0.913
HOWL	0.902
BNIXU	0.887
GAINL	0.884
OLMA	0.874
IPKW	0.873
EOLS	0.87
ALGS	0.867
LILAK	0.867
ISNS	0.866

10 Most Negative Correlations
MMAC	-0.89
BOCH	-0.886
SHSP	-0.857
PEP	-0.832
NETE	-0.826
AMRB	-0.825

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immunic Inc Correlation - Currency/Commodity

-0.91
( very strong negative )

0.54
( weak )

0.00
( neutral )

0.71
( moderate )

0.16
( neutral )

Immunic Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-111 000 (0.00 %)
EPS:	$-2.11

Q4	2023
Revenue:	$0
Gross Profit:	$-23 000.00 (0.00 %)
EPS:	$-0.480

Q3	2023
Revenue:	$0
Gross Profit:	$-34 000.00 (0.00 %)
EPS:	$-0.510

Q2	2023
Revenue:	$0
Gross Profit:	$-22 000.00 (0.00 %)
EPS:	$-0.540

Financial Reports:

No articles found.

Immunic Inc

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.